PMID- 11494034
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20190605
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 19
IP  - 3
DP  - 2001 Sep
TI  - Fluorescence in situ hybridization to assess transitional changes of aneuploidy 
      for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following 
      anti-androgen therapy.
PG  - 543-9
AB  - There have been few detailed studies conducted on the cell population in relation 
      to cytogenetic changes between the pre- and post-treatment periods in patients 
      with prostate cancer. We investigated numerical chromosome changes associated 
      with anti-androgen therapy, using fluorescence in situ hybridization (FISH). FISH 
      using chromosome-specific centromeric probes was used to assess transitional 
      changes in the frequency of aneuploidy for chromosomes 7, 8, 10, 12, 16, X, and Y 
      in prostate cancer during the pre- and post-treatment periods. Gains of 
      chromosomes 7, 8 and 12 were notable in the pre-treatment samples (8 out of 9 
      cases in chromosome 7; 8 out of 9 cases in chromosome 8; 7 out of 9 cases in 
      chromosome 12), while a notable reduction in the number of cells with extra 
      copies of these chromosomes was observed in post-treatment specimens. Other 
      chromosomes did not show noticeable change in their FISH signals at each phase of 
      clinical treatment in all 9 cases. Changes in cell number with high ploidies of 
      chromosome 7, 8 and 12 reflect the clinical effects of anti-androgen therapy at 
      the early phase, which might explain the androgen dependency of metastatic 
      prostate cancer cells.
FAU - Kasahara, K
AU  - Kasahara K
AD  - Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
FAU - Taguchi, T
AU  - Taguchi T
FAU - Yamasaki, I
AU  - Yamasaki I
FAU - Karashima, T
AU  - Karashima T
FAU - Kamada, M
AU  - Kamada M
FAU - Yuri, K
AU  - Yuri K
FAU - Shuin, T
AU  - Shuin T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Androgen Antagonists)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/genetics/secondary
MH  - Aged
MH  - Androgen Antagonists/*therapeutic use
MH  - *Aneuploidy
MH  - Bone Neoplasms/*drug therapy/genetics/secondary
MH  - Chromosome Aberrations/genetics
MH  - Chromosome Disorders
MH  - Chromosomes, Human/*genetics
MH  - Chromosomes, Human, 6-12 and X/genetics
MH  - Chromosomes, Human, Pair 16/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen
MH  - Prostatic Hyperplasia/drug therapy/genetics/pathology
MH  - Prostatic Neoplasms/*drug therapy/genetics/pathology
MH  - Sex Chromosomes/*genetics
MH  - X Chromosome/genetics
MH  - Y Chromosome/genetics
EDAT- 2001/08/09 10:00
MHDA- 2001/10/05 10:01
CRDT- 2001/08/09 10:00
PHST- 2001/08/09 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/08/09 10:00 [entrez]
AID - 10.3892/ijo.19.3.543 [doi]
PST - ppublish
SO  - Int J Oncol. 2001 Sep;19(3):543-9. doi: 10.3892/ijo.19.3.543.